* * Welcome to Immunize.org’s Ask the Experts resources. This Ask the Experts question is presented by Immunize.org’s Kelly L. Moore, MD, MPH.
Question:
When do you consider RSV preventive antibody for an infant whose mother received RSV vaccine as recommended?
Answer:
In rare circumstances, nirsevimab (Beyfortus, Sanofi) may be considered for infants in their first RSV season who were born to RSV-vaccinated mothers. These situations may include:
* infants born to mothers who have health conditions that might prevent an adequate maternal immune response to vaccination (an immunocompromising condition caused by disease or immunosuppressive treatment)
* infants whose mothers have conditions associated with reduced transplacental antibody transfer (such as a mother living with HIV infection)
infants who might have lost maternal antibodies, such as those who have undergone cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO)
* infants with substantially increased risk for severe RSV disease (such as hemodynamically significant congenital heart disease or intensive care admission requiring oxygen at hospital discharge).
Infants and children age 8–19 months who are at increased risk for severe RSV disease and are entering their second RSV season are recommended to receive nirsevimab regardless of history of maternal vaccination.
About Ask the Experts
Immunize.org established Ask the Experts to provide practical answers to clinical questions about vaccines and vaccine administration. Our Immunize.org experts have answered more than 1,200 clinical questions like this one based on ACIP recommendations. You can find all of these questions and answers on our "Ask the Experts" page at [ Ссылка ].
About Immunize.org
Immunize.org supports healthcare professionals with educational resources and advocates to remove barriers to vaccination for all. We create and distribute educational materials for healthcare professionals and the public that enhance the delivery of safe and effective immunization services. We work to improve national and state vaccine policy. Immunize.org also facilitates communication about the safety, efficacy, and use of vaccines within the broad immunization community of patients, parents, healthcare organizations, and government health agencies.
Stay up to date by subscribing to our free weekly newsletter, IZ Express, including ATE Special Editions at [ Ссылка ].
Stay current on immunization news; follow us on your favorite social media platform:
Instagram: @ImmunizeOrg
Facebook: @ImmunizeOrg
LinkedIn: @Immunize.org
Legal Disclaimer: [ Ссылка ]
#savelivesimmunize #immunizeorg #vaccinessavelives #vaccineswork #vaccination
